El interés en corto de Veea da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Veea. Los datos de interés en corto se actualizan cada dos semanas.

Veea (NASDAQ:VEEA) Bolsa, Informe de interés en corto

Veea

Veea Inc is a company providing edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. It has first-in-class VeeaHub smart computing hubs integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.

Veea Inc

PO Sync allows merchants to put replenishment on auto-pilot with a fully-integrated, trail-blazing wholesale network that redefines and simplifies the buying process for retailers and brands across the globe. &nbsp;
MONTREAL, April 3, 2025 /PRNewswire/ -&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4397861-1&amp;h=4128617570&amp;u=https%3A%2F%2Fwww.lightspeedhq.com%2F&amp;a=Lightspeed+Commerce+Inc.">Lightspeed Commerce Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#TSX">LSPD</a>) ("Lightspeed" or the "Company"), the one-stop commerce platform empowering merchants to provide the best omnichannel experiences, today unveils Inventory Replenishment directly integrated into Lightspeed Retail, the premiere Point of Sale for ambitious retailers. Tapping into Lightspeed NuORDER, this launch introduces capabilities to streamline wholesale processes for leading brands and retailers, including a new, rebranded name for Lightspeed's wholesale network.
PO Sync allows retailers to place order replenishments within Lightspeed's POS platform and send to their suppliers in one click. This takes a process that is manual, time-intensive and repetitive and makes it automated and data-driven, helping retailers put replenishment on auto-pilot.
PO Sync is the latest enhancement from Lightspeed as part of Lightspeed NuORDER.
Lightspeed NuORDER, brings together over 4,000 brands with 100,000+ retailers as part of a wholesale network that is transforming how retailers and suppliers do wholesale commerce. Through product and brand discovery, automated ordering and replenishment and access to industry and sell through insights, both retailers and brands experience a wholesale partnership that's more profitable, data-driven and can be managed in less time with less steps making it easier for both brands and retailers to grow their business.

News

LSPD

TSX:LSPD

Lightspeed Commerce Launches PO Sync, Simplifying Wholesale Ordering And Automating The Replenishment Process Through Lightspeed Retail And NuORDER Network, Empowering Merchants With Data-Driven, Time-Saving Solutions

RESTON, Va., April 3, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4395237-1&amp;h=847953387&amp;u=https%3A%2F%2Fwww.leidos.com%2F&amp;a=Leidos">Leidos</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) today announced a new contract to provide signals intelligence (SIGINT) capabilities, engineering, analysis and reporting tools to the National Security Agency (NSA). The base year plus four option years single-award contract has a ceiling value of $390 million.
Leidos will perform a wide range of technical, engineering, systems administration and management functions. Tasks include delivery of SIGINT capabilities, analysis and reporting tool modifications, engineering services, lab and testbed management, integration and testing, deployment, training, and sustainment of a subset of NSA systems.
"Tailored and unique SIGINT solutions for the military and intelligence community are critical to delivering information superiority at speed," said Roy Stevens, Leidos National Security Sector president. "This contract will leverage Leidos' engineering and technical expertise, as we expand our work with the NSA."
Leidos combines expertise in cyber and IT managed services, as well as radar, sensors and other technologies, to develop SIGINT technologies, with end-users always in mind. Those technologies include resilient communications that operate through interruption to keep critical mission data flowing.

Contracts

LDOS

Leidos Receives $390M NSA Signals Intelligence Contract

Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) (the "Company"), a global leader in e-commerce for technology products, today announced that the twenty-to-one share combination (commonly referred to as a reverse stock split) of its common shares will become effective on April 7, 2025 upon the filing of the Amended and Restated Memorandum and Articles of Association with the Registry of Corporate Affairs in the British Virgin Islands, which will result in a proportionate increase to the par value of the Company's common shares from $0.021848 per share to $0.43696 per share. As previously announced, the share combination was approved by the Company's board of directors and the controlling shareholders of the Company by written consent. While the CUSIP number for the Company's common shares will change from G6483G 100 to G6483G 209, the common shares will continue to trade on the Nasdaq Capital Market under the symbol "NEGG." The share combination is intended to enable the Company to continue to meet minimum Nasdaq listing price per share requirements and will affect all shareholders proportionately. The share combination will not alter any shareholder's percentage interest in the Company, except for fractional shares created by the share combination, which will be exchanged for cash.
The Company's transfer agent, Computershare Inc. ("Computershare"), is acting as the exchange and paying agent for the share combination. Registered holders are encouraged to contact Computershare and beneficial holders are encouraged to contact their bank, broker or other nominee with any questions.

Stock Split

NEGG

Newegg Commerce Announces 20-For-1 Reverse Stock Split Effective April 7, 2025

VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) (BMV:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#BMV">ZENA</a>) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone-as-a-Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces that it has closed the acquisition of Wallace Surveying Corporation ("Wallace") of West Palm Beach, Florida, a well-established land survey company with thirty years of experience. Wallace provides construction and land development surveys delivering accurate and reliable data that supports project planning and design for developers, contractors, engineers, and architect customers.
This is ZenaTech's second acquisition in the Southeast region as part of a larger national roll-up strategy to disrupt the land survey industry by accelerating the use of drones for speed and accuracy benefits. The acquisition also further powers the Company's national Drone as a Service, or DaaS, business as the third US acquisition set to provide access to the ZenaDrone 1000 and the IQ series. These multifunction drones are set to provide a variety of services including power line inspections, precision agriculture, law enforcement, and search and rescue for natural disasters such as hurricanes.
"Wallace Surveying Corporation is well respected in the South Florida business community with longstanding existing customer relationships. Its team brings considerable expertise toward our goal of innovating land surveys at scale leveraging advanced drone data collection, data management, mapping and digital deliverables. This acquisition is another step towards our vision to create a national DaaS business, bringing AI drone efficiencies and precision to a variety of legacy verticals and manual tasks," said CEO Shaun Passley, Ph.D.
ZenaTech's Drones as a Service or DaaS model is similar to Software as a Service (SaaS), but instead of providing software solutions over the Internet, the company will offer ZenaDrone solutions and services on a subscription or pay-per-use basis. Customers can conveniently access drones for eliminating manual or time-consuming tasks achieving more precision, such as for surveying, inspections, security and law enforcement, or farming precision agriculture applications, without having to buy, operate, or maintain the drones themselves.
The DaaS business model offers customers such as government agencies, real estate developers, construction firms, farmers or energy companies reduced upfront costs as there is no need to purchase expensive drones, as well as convenience, as there is no need to manage maintenance and operation. The model also offers scalability to use more often or less often based on business needs and enables access to advanced drone technology sensors or attachments like spraying, without the need for specialized training.
Accurate land surveys are essential for the planning, designing, and executing of roads, bridges, and building projects for cities, commercial, and residential projects, and are required for legal purposes. Remotely piloted drones with an array of sensors and cameras, LiDAR (Light Detection and Ranging), and GPS systems for capturing high-resolution pictures and data are revolutionizing the land survey industry gathering aerial data across expansive terrains in a matter of hours instead of weeks or months using more traditional photogrammetry methods.
According to <a href="https://www.globenewswire.com/Tracker?data=miePsDL-_0-Ay_GO6mmTWFtiQ22U5GrrPlJlQ_3uafN9VuNFYYlwXlFDVfKCSgO37-ZOC93jy6ThGS6N2Oqw4IOSWjPWkkBGznF3Q--wPszcCBiUw1rZquVRFH4YYpZW">Fact.MR</a>, the global drone surveying market is poised for substantial growth and is expected to be worth over USD $8 billion globally by 2030. This market is expanding at a CAGR of 15-20%, driven by increasing demand from industries such as construction, agriculture, and infrastructure development. In particular

BMV:ZENA

ZENA

ZenaTech Achieves Second Southeast Region Acquisition, Wallace Surveying Corporation, To Become Third Acquisition To Power Its National Drone As A Service Business

Biotech

General

PCRX

Pacira BioSciences Announces Dosing Of First Patient In Phase 2 Study Assessing Safety And Efficacy Of PCRX-201 For Knee Osteoarthritis Treatment

<ul>
<li>CREXONT added to 3 large national formularies: Veterans Administration, UnitedHealthcare and CVS Health</li>
<li>Increases insurance coverage to over 50% of covered lives</li>
<li>CREXONT was approved by the U.S. FDA to treat Parkinson's disease in 2024</li>
</ul>
Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that three large insurance coverage accounts, the Veterans Administration (VA), UnitedHealthcare and CVS Health, have added CREXONT&#xAE; (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson's disease (PD) to their national prescription drug formularies. CREXONT is a prescription medication for the treatment of PD approved by the U.S. FDA in August 2024.
This expanded coverage increases CREXONT's total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50%. The Company had initially set a goal to surpass 50% coverage by the end of 2025, making this milestone—achieved nine months ahead of schedule—a testament to Amneal's commitment to broadening patient access. The VA has already added the product in its national formulary, covering approximately 10% of U.S. PD patients. UnitedHealthcare will add CREXONT to its standard prescription drug lists in the second quarter of 2025. In addition, CVS Health will add CREXONT as a "preferred" product to its national formulary on July 1, 2025.

AMRX

Amneal Announces Expanded Coverage For CREXONT To Enhance Access For Parkinson's Disease Patients In The U.S.; Increases Insurance Coverage To Over 50% Of Covered Lives

Gencor Industries, Inc. (the "Company" or "Gencor") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENC#NYSE">GENC</a>) previously reported that it needed additional time to complete its audit of the Annual Report on Form 10-K for the year-end September 30, 2024. In connection with this delay, the Company filed a Form 12b-25 with the Securities and Exchange Commission with respect to the Company's Annual Report on Form 10-K for the year-end September 30, 2024. The Company similarly filed a Form 12b-25 with the Securities and Exchange Commission with respect to its Quarterly Report on Form 10-Q for the period ended December 31, 2024.
Unaudited Preliminary Results:
Set forth below are select unaudited preliminary estimates of operating results for the fiscal 2025 first quarter ended December 31, 2024 and cash and marketable securities and backlog at March 31, 2025.
The Company anticipates reporting revenue of approximately $31 million for the first quarter of fiscal 2025, compared to $26 million for the first quarter of fiscal 2024.
At March 31, 2025, the Company had approximately $144 million in cash and marketable securities, compared with approximately $117 million at March 31, 2024, with no short-term or long-term debt.
The Company's backlog at March 31, 2025 was approximately $24 million.

Guidance

GENC

Gencor Preliminary Q1 Revenue Of ~$31M Up From $26M YoY

<ul>
<li>On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)</li>
<li>U.S. FDA BLA submission for accelerated approval planned for 2H 2025</li>
</ul>
BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN).
"We are grateful for the IgAN community's strong interest in the clinical development of atacicept that helped drive us towards completing full enrollment in the ORIGIN 3 trial with a total of 431 participants. Complete enrollment represents another key milestone on the path to potential approval of the first B cell modulator targeting both BAFF and APRIL for IgAN," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "We anticipate the 36-week primary efficacy endpoint data from the trial this quarter, which supports our planned Biologics License Application for an accelerated approval to the U.S. FDA in the second half of 2025. ORIGIN 3 follows the positive long-term results from the ORIGIN Phase 2b trial that demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and proteinuria, and showed stabilized kidney function through 96 weeks, positioning atacicept as a potential best-in-class IgAN therapy. Pending the submission and thorough FDA review of the BLA, we would look forward to a potential PDUFA date and commercial launch in 2026."
The ORIGIN 3 trial (NCT04716231) is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of atacicept in patients with IgAN who have persistent proteinuria and remain at high risk of disease progression. Participants are randomized 1:1 to at-home self-administered once-weekly subcutaneous injections of atacicept 150 mg or placebo for a 104-week double-blind period, followed by a 52-week open-label extension.
The primary efficacy endpoint is the change in proteinuria as evaluated by urine protein to creatinine ratio (UPCR) through 36 weeks in an interim analysis of at least 200 participants. The key secondary efficacy endpoint is change in kidney function as measured by estimated glomerular filtration rate (eGFR) through 104 weeks in the full study population.

VERA

Vera Therapeutics Announces Full Enrollment In ORIGIN Phase 3 Trial For Atacicept In IgAN

The American Association of Individual Investors (AAII) survey revealed that bearishness, at 61.9%, continued to outpace bullish and neutral sentiment this week, marking a week-over-week rise in pessimism.
What Happened: The most recent results from the AAII Sentiment Survey, which tracks investor sentiment weekly from Thursday to Wednesday, revealed an increase in pessimism. Specifically, the proportion of individual investors expressing a bearish outlook on the stock market&#8217;s short-term trajectory surged by almost 10%, climbing from 52.2% to 61.9%.
This rise in the bearish sentiment marked a 16-year high from March 2009, as highlighted by Kevin Gordon, the director and senior investment strategist at Charles Schwab &amp; Co., in an X-post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">AAII bears highest since March 2009 <a href="https://t.co/OYzAj9O9yP">pic.twitter.com/OYzAj9O9yP</a>
&mdash; Kevin Gordon (@KevRGordon) <a href="https://twitter.com/KevRGordon/status/1907751165854429362?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Bearish sentiment has now persisted above the 50% level for six consecutive weeks. This prolonged period of pessimism follows last week&#8217;s occurrence, which was the <a href="https://www.benzinga.com/markets/futures/25/03/44534664/bearish-sentiment-mirrors-35-year-old-pattern-hovering-over-50-for-5-weeks-expert-cites-incredible-buying-opportunities-from-past">first five-week stretch</a> of such elevated bearishness since similar patterns emerged in October 1990 and 2022. 
The historical average of bearish sentiments stood at 31%, which was half of the current pessimism among the participants of the AAII survey.
The bullish sentiment for the week stood at 21.8%, down from 27.4% last week, whereas the neutral sentiment shrank from 20.4% to 16.3% this week.
See Also: <a href="https://www.benzinga.com/25/04/44622754/tariffs-are-most-expensive-and-masochistic-could-cost-30-trillion-to-the-economy-erasing-300k-per-family-explains-former-treasury-secretary-larry-summers">Trump Tariffs Could Cost $30 Trillion Or About $300,000 Per Family, Says Former Treasury Secretary Larry Summers: &#8216;Most Expensive And Masochistic&#8217;</a>
Why It Matters: The worries about President Donald Trump's tariffs have worried the stock markets, increasing the pessimism among investors.
President Trump, citing a "large and persistent trade deficit," declared a <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted">trade emergency Wednesday</a>, utilizing a 1977 law to impose reciprocal tariffs.
The White House detailed the tariffs, emphasizing "Treat us like we treat you." While Canada and Mexico were exempt, China, Vietnam, Cambodia, and Sri Lanka faced the highest increases, leading gold prices to a record $3,167.71 and prompting a flight to safe-haven assets.
However, the respondents to AAII's special question this week about having gold in their portfolio were largely negative. The survey asked its participants if they held gold or other precious metals in their portfolio, either directly or through an ETF.
About 60.1% of respondents said "no," 18.5% responded "yes," and others admitted to holding both mining companies and precious metals in their portfolios.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Thursday. The SPY was down 3.30% to $545.87, while the QQQ declined 3.80% to $458.06, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Gold prices were lower by 0.17% at $3,127.80 after scaling a fresh record of $3,167.71 per ounce.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44623855/ray-dalio-warns-of-abrupt-unconventional-changes-in-markets-heres-how-the-tariff-machine-affects-currency-monetary-and-fiscal-policies">Ray Dalio Warns Of &#8216;Abrupt, Unconventional Changes&#8217; In Markets: Here&#8217;s How The &#8216;Tariff Machine&#8217; Affects Currency, Monetary And Fiscal Policies</a></li>
</ul>
Image via Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Economics

Markets

ETFs

Wall Street Worries Mount As Bearish Sentiment Hits Highest Level Since 2009 Amid Trump's Tariffs

<a href="https://www.globenewswire.com/Tracker?data=8ukNSezJvre1fdrHP-8DOmIkbv5HMNurS_7vKaN-s7OTkx5wkhgCIdWORIDuwL6k0fsV7ZYJyuoSB7LAf-eibvPiiFfPn_dKBraV3_5rYx0=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group,&nbsp;today announced that it is being forced to sell its Bitcoin Treasury after having been blocked from selling shares or raising funds, and specifically from using investor funds to buy Bitcoin by the United States District Court Southern District of New York (SDNY).
As previously reported by the Company, on October 30, 2024 Genius initiated arbitration procedures to terminate its Asset Purchase Agreement (APA) with Fatbrain AI (LZGI), and on December 17, 2024 both parties agreed to a preliminary injunction on the Company's shares related to the APA (Case 1:24-cv-08468-MKV).
This took place after LZGI's shareholders filed a lawsuit against LZGI and its officers, Michael Moe and Peter Ritz alleging a history of fraud, including in their actions related to the APA (Case 1:24-cv-07551), and after the SEC filed shareholder fraud allegations for defrauding LZGI shareholders amongst others (Case 2:24-cv-00918).
Further to these filings, on February 14, 2025, Moe and Ritz filed for a Temporary Restraining Order (TRO) and Preliminary Injunction (PI) to prevent Genius from selling any shares, or raising any funds, including through the use of its $150m ATM funding, and specifically from buying Bitcoin. On the same day, the TRO was granted, and on March 13, 2025, the SDNY granted the PI.
Over the last six weeks, Genius has filed multiple letters and motions to the court explaining that the TRO and PI did not maintain the status quo pending arbitration, that they were based on false statements designed to defraud the court, and the intent of the filing of the TRO and PI was to extort further money from Genius.
Genius also filed with the court a transcript of a meeting with Ritz and Genius executives recorded in New York on February 27, 2025 in which Ritz explained in detail how he has weaponized the TRO and PI process in order to extort millions more out of Genius to aid his personal scheme to defraud his LZGI shareholders.
This transcript has also been filed by LZGI's shareholders in their derivative case against LZGI, Moe and Ritz in the United States District Court Southern District of Florida (Case 1:25-cv-21062-JEM). Genius, which was initially named in both LZGI shareholder lawsuits has subsequently been voluntarily dismissed from both.
To date, the PI has remained in effect. As a result, Genius has had its financing and Bitcoin Treasury activities blocked by court order for the last six weeks, in direct opposition to the wishes, consent and approvals of the Company's Board and shareholders. As the injunction also prevents Genius from issuing share compensation to employees as part of their long standing employment agreements, Genius is in the unusual position of being legally compelled by a US court to directly break Singapore law.
As a result of the PI, which legally blocks Genius from being able to fund its operations, Genius is currently taking the following actions:
<ul>
<li>Pursuing an appeal with the second circuit: The Company filed an emergency motion to vacate the PI and for an immediate administrative stay with the United States Court of Appeals for the Second Circuit on March 19, 2025, and is awaiting the outcome of the appeal. &nbsp;</li>
<li>Restructuring operations: With the legal block on the Company's ability to issue shares or raise funds, the Company is taking steps to downsize its operations, including closing various divisions and cancelling all event sponsorships, marketing activity, and investing activities until such time that the Company is legally able to resume its growth plans. &nbsp;</li>
<li>Downsize its Bitcoin Treasury: By blocking all share sales and all receipt of investor funds, the Court is forcing the Company to sell its Bitcoin Treasury to fund its operations. Genius is taking all necessary measures to minimize Bitcoin sales but anticipates that it will need to downsize its Bitcoin Treasury in the coming months in the event the PI remains in place. As at today's date, the Company has had to reduce its Bitcoin holdings from 440 Bitcoin to 430 Bitcoin. &nbsp;</li>
<li>Retaining its public listed status: The LZGI complaints against Ritz and Moe details an ongoing history of defrauding investors by diverting funds for personal gain and pushing the companies they target into insolvency and closure. The SEC complaint details a pattern of defrauding investors and short selling companies including LZGI. Genius has provided evidence to the court that this same modus operandi is now being applied to Genius. The Company is committed to fighting against this fraudulent behaviour using all legal means available. &nbsp;</li>
</ul>

Legal

Genius Group Announces That It Is Being Forced To Sell Its Bitcoin Treasury After Having Been Blocked From Selling Shares Or Raising Funds, And Specifically From Using Investor Funds To Buy Bitcoin By The United States District Court Southern District Of New York

<ul>
<li>Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally</li>
<li>TMJ causes pain and stiffness in the jaw, making it difficult to chew</li>
<li>TMJ osteoarthritis currently has no long-term effective treatments</li>
</ul>
Ness-Ziona, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>, the "Company" or "Enlivex"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed in an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra&#x2122; for injection into the temporomandibular joint (TMJ) in patients suffering from TMJ osteoarthritis.
The study will be conducted by the Rheumatology Unit at Sheba Medical Center in collaboration with the Department of Oral and Maxillofacial Surgery at Sheba Medical Center. Notably, Sheba Medical Center was recently ranked among the top 10 hospitals in the world by Newsweek.
Dr. Einat Galamidi, CMO of Enlivex, commented, "This study will provide a preliminary evaluation of the safety and potential effect of AllocetraTM for the treatment of TMJ osteoarthritis, which affects a joint that is critical for daily function. We are pleased to report that the injection of AllocteraTM into the first patient's TMJ was successfully completed with no complications."
The trial currently plans to recruit six patients who have insufficiently responded to conventional therapies for TMJ osteoarthritis. The trial's primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and efficacy endpoints will assess changes from baseline in TMJ pain, joint functionality, and other disease parameters for up to 12 months following administration of Allocetra&#x2122;.

ENLV

Enlivex Doses First Patient In Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis

CNTM

ConnectM Technology Solutions Board To Evaluate $46.5M Buy-Out Offer

<h3>Gainers</h3>
<ul>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock rose 15.9% to $0.02 during Thursday's pre-market session. The market value of their outstanding shares is at $2.5 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) stock increased by 12.84% to $0.52. The market value of their outstanding shares is at $5.1 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares increased by 11.62% to $1.44. The company's market cap stands at $27.6 million. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock increased by 9.25% to $1.18. The company's market cap stands at $10.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) shares decreased by 32.6% to $17.01 during Thursday's pre-market session. The market value of their outstanding shares is at $410.4 million. </li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares declined by 29.42% to $176.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Mister Car Wash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCW#NASDAQ">MCW</a>) shares declined by 23.08% to $6.2. The company's market cap stands at $2.0 billion. </li>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares decreased by 20.81% to $1.37. The market value of their outstanding shares is at $7.4 million. </li>
<li>Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) stock decreased by 17.44% to $1.8. The company's market cap stands at $52.0 million. </li>
<li>Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) stock fell 16.38% to $28.2. The company's market cap stands at $3.5 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CJET

LEGH

TCTM

10 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Primech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) stock increased by 17.6% to $0.92 during Thursday's pre-market session. The market value of their outstanding shares is at $34.9 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock moved upwards by 12.84% to $0.64. The market value of their outstanding shares is at $9.6 million. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares increased by 7.97% to $0.81. The market value of their outstanding shares is at $23.5 million. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) shares rose 7.01% to $1.07. The company's market cap stands at $27.2 million. </li>
<li>FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares rose 6.1% to $3.13. The company's market cap stands at $40.2 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>NL Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NL#NYSE">NL</a>) shares moved upwards by 6.09% to $8.35. The market value of their outstanding shares is at $407.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) stock decreased by 32.5% to $9.0 during Thursday's pre-market session. The company's market cap stands at $859.5 million. </li>
<li>Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) stock decreased by 24.71% to $21.0. The company's market cap stands at $277.1 million. The company's, Q2 earnings came out yesterday. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock fell 23.85% to $4.79. The company's market cap stands at $2.8 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) shares fell 14.26% to $4.45. The market value of their outstanding shares is at $55.6 million. </li>
<li>Covenant Logistics Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVLG#NYSE">CVLG</a>) stock fell 12.59% to $20.21. The market value of their outstanding shares is at $532.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

BIYA

CVLG

EHGO

FTCI

PMEC

11 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Powell Max (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) shares moved upwards by 54.9% to $0.69 during Thursday's pre-market session. The market value of their outstanding shares is at $10.1 million. </li>
<li>SHF Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) stock rose 31.52% to $4.13. The company's market cap stands at $11.5 million. </li>
<li>Old Point Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPOF#NASDAQ">OPOF</a>) stock rose 17.18% to $35.05. The company's market cap stands at $177.9 million. </li>
<li>MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNGD#NYSE">FNGD</a>) shares increased by 13.91% to $19.5. </li>
<li>Atlantic American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAME#NASDAQ">AAME</a>) shares moved upwards by 6.32% to $1.68. The market value of their outstanding shares is at $34.2 million. </li>
<li>AtlasClear Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#AMEX">ATCH</a>) shares increased by 6.15% to $0.59. The market value of their outstanding shares is at $3.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Primis Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) stock decreased by 47.8% to $5.01 during Thursday's pre-market session. The company's market cap stands at $123.8 million. </li>
<li>Ponce Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDLB#NASDAQ">PDLB</a>) shares declined by 37.62% to $8.01. The company's market cap stands at $181.5 million. </li>
<li>RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) stock fell 32.03% to $11.25. The market value of their outstanding shares is at $199.4 million. </li>
<li>CNB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCNE#NASDAQ">CCNE</a>) shares decreased by 28.88% to $16.01. The company's market cap stands at $335.8 million. </li>
<li>Penns Woods Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWOD#NASDAQ">PWOD</a>) shares fell 21.98% to $22.01. The company's market cap stands at $167.5 million. </li>
<li>PCB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCB#NASDAQ">PCB</a>) shares decreased by 19.13% to $15.01. The market value of their outstanding shares is at $215.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAME

ATCH

CCNE

FNGD

FRST

OPOF

PDLB

PMAX

PWOD

SHF Holdings, Inc. - Class A Common Stock

SHFS

12 Financials Stocks Moving In Thursday's Pre-Market Session

<ul>
<li>Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025</li>
<li>Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aldeyra.com%2F&amp;esheet=54232964&amp;newsitemid=20250403220331&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=231423ca5b7730a157e413b7ea8d690e">Aldeyra Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were identified, the FDA stated in the letter that the NDA "failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes" and that "at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye" should be conducted. The letter identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatment arms.

ALDX

Aldeyra Therapeutics Receives Complete Response Letter From The U.S. FDA For The Reproxalap New Drug Application For The Treatment Of Signs And Symptoms Of Dry Eye Disease

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares moved upwards by 179.6% to $0.63 during Thursday's pre-market session. The company's market cap stands at $4.5 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock increased by 122.46% to $3.07. The company's market cap stands at $4.4 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 62.76% to $5.29. The company's market cap stands at $3.2 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock moved upwards by 44.95% to $2.13. The company's market cap stands at $41.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock increased by 21.08% to $0.36. The company's market cap stands at $3.0 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 13.64% to $0.15. The market value of their outstanding shares is at $4.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) stock fell 29.2% to $18.49 during Thursday's pre-market session. The market value of their outstanding shares is at $748.7 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares fell 24.18% to $0.67. The market value of their outstanding shares is at $10.5 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) stock fell 23.01% to $4.1. The market value of their outstanding shares is at $244.1 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock fell 22.95% to $0.23. The company's market cap stands at $4.6 million. </li>
<li>ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) stock fell 20.11% to $4.61. The market value of their outstanding shares is at $176.0 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 19.56% to $1.81. The market value of their outstanding shares is at $4.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

BIAF

GNPX

ITOS

OSRH

PTIX

QNRX

RXST

SBFM

TIVC

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

ATLANTA and SUNNYVALE, Calif., April 3, 2025 /PRNewswire/ -- Google Cloud today announced an expanded multi-year partnership with Papa Johns to revolutionize the pizza maker's ordering and delivery experience using the power of artificial intelligence (AI). Through the partnership Papa Johns has created an innovation team, named PJX, that will leverage Google Cloud's AI, data analytics and machine learning (ML) capabilities to provide a more frictionless and consistent experience for customers both inside its restaurants and throughout its digital channels.
Through its partnership with Google Cloud, Papa Johns expects to drive success through increased order frequency, higher-value orders, reduced customer service costs, improved customer satisfaction (via a chatbot powered by Google Cloud's technology) – and ultimately, more joyful pizza experiences.
"At Papa Johns, our aspiration is to be the best pizza makers in the business. Being the best means we are crafting great pizza and providing every single customer a superior experience along every part of their journey – from ordering, to delivery, to our loyalty program," said Todd Penegor, President and CEO, Papa Johns. "Our partnership with Google Cloud will enable us to take personalization to the next level. We're not just reacting to orders – we're anticipating our customers' needs and proactively providing tailored recommendations and offers. This isn't just about convenience; it's about creating a truly joyful and personalized pizza experience that builds lasting loyalty."

GOOG

PZZA

Papa Johns And Google Cloud Enters Partnership To Deliver AI-Powered Pizza Experiences

Founder &amp; CEO of Professional Capital Management, <a href="https://www.benzinga.com/25/03/44433988/tether-is-now-too-big-to-fail-says-anthony-pompliano-citing-its-growing-role-in-us-treasury-markets">Anthony Pompliano</a> has praised the new tariffs introduced by President Donald Trump on Wednesday, arguing that they highlight the inefficiencies of traditional financial systems and bolster the case for decentralized finance solutions like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
What Happened: Speaking on a <a href="https://x.com/APompliano/status/1907532904403489074">podcast</a>, Pompliano linked the tariffs to broader economic shifts, while the crypto market faced significant declines amid fears of a global trade war sparked by the new policy.
Pompliano emphasized that the tariffs underscore the vulnerabilities of centralized banking systems, which he claims have been weaponized against businesses for political reasons. 
He recounted the Trump family's experience with banks like Capital One, Chase, Bank of America and First Republic, which canceled their accounts during Donald Trump's presidency, a move he described as "political lawfare."
This experience, shared by Eric Trump on the same broadcast, drove the family to embrace cryptocurrency. 
"I realized the power that these banks had, and I realized how they were exerting that power, and they were canceling businesses all over our country," Eric Trump said, explaining his shift toward crypto.
The tariffs, unveiled by Trump in a <a href="https://www.benzinga.com/25/04/44622346/trumps-reciprocal-tariff-math-a-masterclass-in-economic-absurdity">White House Rose Garden ceremony</a>, impose a "reciprocal tariff rate" set at 50% of what trading partners charge the U.S., targeting countries like Vietnam, Cambodia and Sri Lanka with the steepest increases, while sparing Canada and Mexico.
Trump called the move "our Declaration of Economic Independence," stating, "April 2nd will forever be remembered as the day American industry was reborn."
However, the announcement triggered a sharp decline in crypto markets on Wednesday, with Bitcoin plunging to $82,400 levels from its all-time high of $108,786.
Major altcoins like Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) also traded down 8-10% after the announcement.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44613293/avax-to-outperform-bitcoin-ethereum-reaching-250-by-2029-standard-chartered">AVAX To Outperform Bitcoin, Ethereum, Reaching $250 By 2029: Standard Chartered</a>
Why It Matters: Despite the market downturn, Pompliano sees the tariffs as a validation of crypto's potential to address systemic financial issues.
He argued that blockchain technology offers a more efficient alternative to traditional banking, which he criticized for its outdated practices. 
"There's not a single thing that those banks do that can't be done better, cheaper, more efficiently, faster on blockchain," Pompliano stated, highlighting Bitcoin's role as a store of value and a hedge against real estate.
The broader economic context also includes concerns about the rising costs of materials for AI data centers, as noted by Tory Green, CEO of io.net, a global GPU-power aggregator. 
Green dismissed concerns about rising costs for AI infrastructure caused by tariffs. Instead, he argued that the U.S. should prioritize tapping into idle computing resources rather than building new data centers.
"We're significantly underutilizing the resources we already have," Green said. "The real problem isn't cost—it's inefficiency. We don't need more concrete; we need better connectivity."
Green pointed to benchmarks showing that idle computers still consume up to 60% of the energy used by public cloud systems, and cited a recent MIT Technology Review report showing that 80% of China's AI data centers currently sit idle.
Meanwhile, the Trump family has deepened its involvement in the crypto space, with Eric Trump and Donald Trump Jr. <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44591699/eric-trump-hails-bitcoin-as-one-of-the-greatest-stores-of-value">announcing their investment in a Bitcoin mining company</a>, American Bitcoin, which aims to merge with Trumps American Data Centers to become the world's largest crypto miner and establish its own Bitcoin reserve.
Eric Trump also highlighted the success of their venture, World Liberty Financial, which recently launched a stablecoin, reflecting their belief in crypto's transformative <a href="https://www.benzinga.com/markets/equities/25/04/44620686/sp-500-nasdaq-futures-plunge-over-3-as-trumps-reciprocal-tariff-plan-hits-market-confidence">potential for the U.S. economy.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44613226/bitcoin-braces-for-trump-tariff-announcement-short-term-optimism-has-the-upper-hand-expert">Bitcoin Braces For Trump Tariff Announcement: &#8216;Short-Term Optimism&#8217; Has The Upper Hand, Experts Say</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$DOGE

$SOL

Anthony Pompliano Praises Trump's Tariffs As Catalyst For Crypto Innovation

OTRK

Ontrak Obtains Medicaid Provider Designation In Two New States, Enhancing Direct Service Delivery Capabilities

Penny Stocks

Press Releases

Veea, O.N.E. Amazon, and AECOM Collaborate to Create the Internet of Forests (IoF), a Hybrid Edge-Cloud Computing Solution to Protect the Rainforest Biome and Empower Local Communities

DeepGreenX and Veea Announce Global Strategic Partnership Agreement

Veea Brings Climate-Smart Farming Connectivity Solution to Indiana with Mainstream Fiber

VEEA and MARQUEE Wireless Announce a Strategic Partnership that Extends Cellular Networks with Groundbreaking Smart City and Smart Energy Applications

Veea and Lynxspring Announce Collaborative Strategic Partnership to Accelerate Edge-to-Cloud and Containerization Opportunities

Veea to Ring the Nasdaq Opening Bell on February 5, 2025

Veea Issues Letter to Shareholders

Veea Announces Upcoming Industry Conference Schedule

VEEA® and VAPOR IO Announce a Strategic Partnership to Provide Turnkey AI-as-a-Service Pioneering Solutions for AI Inferencing, Federated Learning, Agentic AI and AIoT

Veea to Participate in the 37th Annual Roth Conference

VEEA

VEEAW

Comments

Veea

Interés en corto

Veea (NASDAQ:VEEA) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL